WO2007044994A3 - Diagnosis and monitoring of chronic renal disease using ngal - Google Patents

Diagnosis and monitoring of chronic renal disease using ngal Download PDF

Info

Publication number
WO2007044994A3
WO2007044994A3 PCT/US2006/040720 US2006040720W WO2007044994A3 WO 2007044994 A3 WO2007044994 A3 WO 2007044994A3 US 2006040720 W US2006040720 W US 2006040720W WO 2007044994 A3 WO2007044994 A3 WO 2007044994A3
Authority
WO
WIPO (PCT)
Prior art keywords
ngal
crf
chronic renal
worsening
disease
Prior art date
Application number
PCT/US2006/040720
Other languages
French (fr)
Other versions
WO2007044994A2 (en
Inventor
Jonathan M Barasch
Prasad Devarajan
Thomas L Nickolas
Kiyoshi Mori
Original Assignee
Childrens Hosp Medical Center
Univ Columbia
Jonathan M Barasch
Prasad Devarajan
Thomas L Nickolas
Kiyoshi Mori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp Medical Center, Univ Columbia, Jonathan M Barasch, Prasad Devarajan, Thomas L Nickolas, Kiyoshi Mori filed Critical Childrens Hosp Medical Center
Priority to EP06826191.6A priority Critical patent/EP1946107B1/en
Publication of WO2007044994A2 publication Critical patent/WO2007044994A2/en
Priority to US11/770,245 priority patent/US20080090304A1/en
Publication of WO2007044994A3 publication Critical patent/WO2007044994A3/en
Priority to US12/750,241 priority patent/US20100184089A1/en
Priority to US13/747,646 priority patent/US20130137122A1/en
Priority to US14/482,193 priority patent/US20180100866A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
PCT/US2006/040720 2005-10-13 2006-10-13 Diagnosis and monitoring of chronic renal disease using ngal WO2007044994A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06826191.6A EP1946107B1 (en) 2005-10-13 2006-10-13 Diagnosis and monitoring of chronic renal disease using ngal
US11/770,245 US20080090304A1 (en) 2006-10-13 2007-06-28 Diagnosis and monitoring of chronic renal disease using ngal
US12/750,241 US20100184089A1 (en) 2006-10-13 2010-03-30 Diagnosis and monitoring of chronic renal disease using ngal
US13/747,646 US20130137122A1 (en) 2005-10-13 2013-01-23 Diagnosis and monitoring of chronic renal disease using ngal
US14/482,193 US20180100866A9 (en) 2005-10-13 2014-09-10 Diagnosis and monitoring of chronic renal disease using ngal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/374,285 2005-10-13
US11/374,285 US20070037232A1 (en) 2005-03-31 2005-10-13 Detection of NGAL in chronic renal disease

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/374,285 Continuation-In-Part US20070037232A1 (en) 2005-03-31 2005-10-13 Detection of NGAL in chronic renal disease
US14/088,638 Continuation US20140080155A1 (en) 2005-03-31 2013-11-25 Detection of ngal in chronic renal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/770,245 Continuation-In-Part US20080090304A1 (en) 2005-10-13 2007-06-28 Diagnosis and monitoring of chronic renal disease using ngal

Publications (2)

Publication Number Publication Date
WO2007044994A2 WO2007044994A2 (en) 2007-04-19
WO2007044994A3 true WO2007044994A3 (en) 2009-04-30

Family

ID=37943604

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/040720 WO2007044994A2 (en) 2005-10-13 2006-10-13 Diagnosis and monitoring of chronic renal disease using ngal
PCT/US2006/040132 WO2007047458A2 (en) 2005-10-13 2006-10-13 Diagnosis and monitoring of chronic renal disease using ngal

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040132 WO2007047458A2 (en) 2005-10-13 2006-10-13 Diagnosis and monitoring of chronic renal disease using ngal

Country Status (6)

Country Link
US (7) US20070037232A1 (en)
EP (4) EP1946105A4 (en)
JP (1) JP4879993B2 (en)
CA (1) CA2625937A1 (en)
ES (1) ES2617520T3 (en)
WO (2) WO2007044994A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8023882B2 (en) * 2004-01-14 2011-09-20 The Nielsen Company (Us), Llc. Portable audience measurement architectures and methods for portable audience measurement
PL1831699T3 (en) * 2004-12-20 2010-04-30 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
JP4865377B2 (en) * 2006-03-28 2012-02-01 国立大学法人 新潟大学 Method for measuring human megalin
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ES2379603T3 (en) 2006-05-30 2012-04-27 Antibodyshop A/S Methods for rapid assessment of the severity of trauma
EP2602624A1 (en) * 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CA2702612C (en) * 2007-10-19 2016-05-03 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
EP2215481B2 (en) * 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia High molecular weight ngal as a biomarker for chronic kidney disease
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
BRPI0912683A2 (en) 2008-05-15 2016-01-26 Transmolecular Inc treatment of metastatic tumors
US20100122355A1 (en) * 2008-07-16 2010-05-13 Neal Paragas Transgenic Reporter Mouse and Method for Use
EP2743702B1 (en) * 2008-08-28 2017-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105021826A (en) * 2008-08-29 2015-11-04 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010045585A2 (en) * 2008-10-16 2010-04-22 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
EP3246707B1 (en) 2008-10-21 2020-09-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2347260A4 (en) * 2008-10-21 2012-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010048670A1 (en) 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
JP2012508177A (en) * 2008-11-05 2012-04-05 アボット・ラボラトリーズ Neutrophil gelatinase-related lipocalin (NGAL) protein isoforms enriched from urine and recombinant Chinese hamster ovary (CHO) cells, and related compositions, antibodies, and methods of enrichment, analysis and use
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010058378A1 (en) 2008-11-21 2010-05-27 Phadia Ab Methods, devices and kits for detecting or monitoring acute kidney injury
NZ592552A (en) * 2008-11-22 2013-12-20 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
JP5424702B2 (en) 2009-04-27 2014-02-26 国立大学法人 新潟大学 Method for detecting renal disease comprising measuring human megalin in urine
US8628930B2 (en) 2009-04-27 2014-01-14 Niigata University Use of megalin in urine as marker for detecting renal disorder
WO2011017614A1 (en) 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2462440B1 (en) 2009-08-07 2017-05-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
MX340078B (en) 2009-11-07 2016-06-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
NZ600828A (en) 2009-12-20 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PL2531206T3 (en) 2010-02-04 2017-12-29 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
SI2666872T1 (en) 2010-02-05 2016-08-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011220413B2 (en) 2010-02-26 2015-07-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20110237513A1 (en) * 2010-03-26 2011-09-29 Pronota N.V. Ltbp2 as a biomarker for renal dysfunction
WO2011140554A1 (en) * 2010-05-07 2011-11-10 The Trustees Of Columbia University In The City Of New York Ngal and urinary tract infection
KR101972173B1 (en) 2010-05-11 2019-04-24 프레드 헛친슨 켄서 리서치 센터 Chlorotoxin variants, conjugates, and methods for their use
EP2576587B1 (en) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
US10436797B2 (en) * 2010-06-03 2019-10-08 Idexx Laboratories, Inc. Markers for renal disease
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5899213B2 (en) 2010-08-06 2016-04-06 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ Pearlcan as a biomarker for renal dysfunction
CN102127564A (en) * 2010-12-09 2011-07-20 南昌大学 Construction of NGAL (neutrophil gelatinase-associated lipocalin) plasmid, and expression of fusion protein of NGAL plasmid
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102775473B (en) * 2012-07-30 2018-10-12 重庆业为基生物科技有限公司 The B cell epitope peptide fragment of human neutrophil gelatinase-associated lipocalin and its application
GB201214440D0 (en) * 2012-08-13 2012-09-26 Randox Lab Ltd Kidney disease biomarker
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
WO2014113558A1 (en) 2013-01-17 2014-07-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
JP6301096B2 (en) * 2013-09-30 2018-03-28 キヤノンメディカルシステムズ株式会社 Medical diagnostic imaging equipment
JP7123329B2 (en) * 2016-05-17 2022-08-23 国立大学法人大阪大学 Kidney disease prognosis prediction method and system
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2018119626A1 (en) * 2016-12-27 2018-07-05 菲鹏生物股份有限公司 Assay kit for neutrophil gelatinase-associated lipocalin
CA3072427C (en) * 2017-08-08 2023-12-05 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US11793836B2 (en) * 2017-09-27 2023-10-24 Inmune Bio Inc Method for treating complications related to acute or chronic hyperglycemia
US10466256B2 (en) 2017-11-03 2019-11-05 Lysulin, Inc. Inhibiting chronic blood and nephrological disorders using lysine-based supplements
US10610544B2 (en) 2017-11-03 2020-04-07 Lysulin, Inc. Insulin resistance and beta cell function using lysine-based supplements
US10653720B2 (en) 2017-11-03 2020-05-19 Lysulin, Inc. Prevention of protein glycation using lysine/zinc supplements
US11255838B2 (en) 2017-11-03 2022-02-22 Lysulin, Inc. Levels, functions, and resistances related to chronic conditions by using lysine-based supplements
CN110229214B (en) * 2018-03-05 2022-03-18 四川大学华西医院 Exosome sustained-release polypeptide hydrogel and preparation method and application thereof
EP3823610A4 (en) * 2018-07-17 2022-08-31 The Regents of the University of California Methods of treating renal disease
WO2020176555A1 (en) * 2019-02-26 2020-09-03 Board Of Regents, The University Of Texas System Renal clearable nanoparticles as exogenous markers for evaluating kidney function
CN110538323A (en) * 2019-09-29 2019-12-06 南京鼓楼医院 Application of anti-LCN 2 antibody in preparation of medicine for treating lupus nephritis
JPWO2021140997A1 (en) 2020-01-09 2021-07-15
EP4101463A1 (en) * 2020-01-31 2022-12-14 National University Corporation Hokkaido University Method for assessing possibility of onset or progression of chronic kidney graft rejection and chronic kidney disease, test kit, and pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004088276A2 (en) * 2003-03-27 2004-10-14 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US552313A (en) * 1895-12-31 Lot brown
US5622871A (en) * 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (en) * 1976-08-05 1985-04-17 Simes ESTERS OF EPININ
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4632901A (en) * 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4731326A (en) * 1984-06-04 1988-03-15 Ortho Diagnostic Systems Inc. Disease diagnosis by detection of shed normal tissue antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
IL85257A (en) * 1987-02-10 1993-02-21 Tanabe Seiyaku Co Pharmaceutical compositions containing 2-(4-methoxyphenyl) 3-acetoxy-5-- (2-(dimethylamino) ethyl) -8-chloro-2,3- dihydro-1,5-benzothiazepin -4 (5h)-one having renal function-improving effect and diuretic effect
US4900662A (en) * 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US4870007A (en) * 1987-12-18 1989-09-26 Eastman Kodak Company Immobilized biotinylated receptor in test device, kit and method for determining a ligand
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
JP2912413B2 (en) * 1990-03-28 1999-06-28 東亜医用電子株式会社 Particle size distribution creation method
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
EP0575906A2 (en) * 1992-06-19 1993-12-29 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. Sandwich immunoassay of beta-N-acetylglucosaminidase and monoclonal antibody used therein
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (en) * 1994-04-21 1994-04-21 Venge A method of diagnosis
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
JP2930427B2 (en) * 1995-04-12 1999-08-03 オイ メディックス バイオケミカ エービー Method and test kit for determining periodontal disease and predicting the risk of developing the disease
US5814462A (en) * 1995-10-02 1998-09-29 The Trustees Of Columbia University In The City Of New York Biochemical markers of ischemia
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
DK0907735T5 (en) * 1996-05-24 2010-06-14 Biogen Idec Inc Tissue regeneration modulators
US5945294A (en) * 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
JP3334558B2 (en) * 1997-04-23 2002-10-15 富士レビオ株式会社 Enzyme immunoassay and test strips
WO1998049559A1 (en) * 1997-04-30 1998-11-05 Maruha Corporation Method for detecting or predicting ischemic diseases
JP3382514B2 (en) * 1997-07-18 2003-03-04 住友ゴム工業株式会社 Rubber roller for paper feed
CA2298439A1 (en) * 1997-08-06 1999-02-18 Zymogenetics, Inc. Lipocalin homologs
US6242246B1 (en) * 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US6114123A (en) * 1999-06-14 2000-09-05 Incyte Pharmaceuticals, Inc. Lipocalin family protein
WO2000078919A1 (en) * 1999-06-18 2000-12-28 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
US20020160495A1 (en) * 2000-09-20 2002-10-31 University Of Medicine And Dentistry Soluble ischemia activated protein
CA2424431A1 (en) * 2000-10-03 2002-04-11 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
CA2425761C (en) * 2000-10-13 2005-11-15 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
US6887714B2 (en) 2000-10-16 2005-05-03 Board Of Trustees Of The University Of Arkansas, N.A. Microvolume immunoabsorbant assays with amplified electrochemical detection
FI20010019A (en) * 2001-01-05 2002-07-06 Biohit Oyj Procedure for the diagnosis of atrophic gastritis
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US6767733B1 (en) * 2001-10-10 2004-07-27 Pritest, Inc. Portable biosensor apparatus with controlled flow
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP1531834A1 (en) * 2002-07-17 2005-05-25 Index Pharmaceuticals AB Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
JP3897117B2 (en) * 2003-09-24 2007-03-22 マルハ株式会社 Method for determining and predicting the severity of pregnancy toxemia, and for evaluating fetal / placental function in pregnancy toxemia
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2005107793A2 (en) * 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
PL1831699T3 (en) * 2004-12-20 2010-04-30 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
ES2379603T3 (en) * 2006-05-30 2012-04-27 Antibodyshop A/S Methods for rapid assessment of the severity of trauma
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20110257140A1 (en) * 2008-10-24 2011-10-20 Inserm (Institut National De La Sante Et De La Rec Herche Medicale) Biomarkers of Mineralocorticoid Receptor Activation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004088276A2 (en) * 2003-03-27 2004-10-14 Children's Hospital Medical Center A method and kit for detecting the early onset of renal tubular cell injury

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MATTHAEUS. T. ET AL.: "Acute Ischemic Renal Failure Induces Expression of Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 in Damaged Tubuli.", CONGRESS OF NEPHROLOGY 2001, KIDNEY BLOOD PRESS RES 2001,, vol. 24, 2001, pages 213 - 240 *
MATTHAEUS. T. ET AL.: "Co-Regulation of Neutrophil Gelatinase-Associated Lipocalin and Matrix Metalloproteinase-9 in the Postischemic Rat Kidney.", J. AM SOC NEPHROL, vol. 12, September 2001 (2001-09-01), XP009065221 *
OHLSSON. K. ET AL.: "Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.", CLINICAL & EXPERIMENTAL IMMUNOLOGY., vol. 131, March 2003 (2003-03-01), pages 528 - 535, XP002997881 *
PAWLUCZYK. I. ET AL.: "Macrophage-induced rat mesangial cell expression of the 24p3-like protein alpha-2-microglobulin-related protein.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1645, 2003, pages 218 - 227, XP004405450 *
See also references of EP1946107A4 *

Also Published As

Publication number Publication date
EP2520936A1 (en) 2012-11-07
ES2617520T3 (en) 2017-06-19
US20130040312A1 (en) 2013-02-14
US20080014644A1 (en) 2008-01-17
EP1946107B1 (en) 2015-02-25
EP1946105A2 (en) 2008-07-23
US20140080155A1 (en) 2014-03-20
US20110143381A1 (en) 2011-06-16
US20100015648A1 (en) 2010-01-21
EP1946107A4 (en) 2009-12-02
EP2469284B1 (en) 2016-12-07
WO2007047458A3 (en) 2009-04-23
EP1946105A4 (en) 2009-12-02
JP2009511913A (en) 2009-03-19
WO2007047458A2 (en) 2007-04-26
EP2469284A1 (en) 2012-06-27
US20090215094A1 (en) 2009-08-27
US20070037232A1 (en) 2007-02-15
JP4879993B2 (en) 2012-02-22
WO2007044994A2 (en) 2007-04-19
EP1946107A2 (en) 2008-07-23
CA2625937A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2007047458A3 (en) Diagnosis and monitoring of chronic renal disease using ngal
Poniatowski et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease
Faubel et al. Mechanisms and mediators of lung injury after acute kidney injury
Rotondi et al. Soluble α-Klotho serum levels in chronic kidney disease
Soni et al. Early diagnosis of acute kidney injury: the promise of novel biomarkers
Venkatapathy et al. Salivary creatinine estimation as an alternative to serum creatinine in chronic kidney disease patients
Eloot et al. Does the adequacy parameter Kt/Vurea reflect uremic toxin concentrations in hemodialysis patients?
Oh et al. Urine output is associated with prognosis in patients with acute kidney injury requiring continuous renal replacement therapy
Voulgaris et al. Chronic kidney disease in patients with obstructive sleep apnea. A narrative review
Rosolowsky et al. Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy
Dousdampanis et al. Diagnosis and management of chronic kidney disease in the elderly: a field of ongoing debate
Perkins et al. Early nephropathy in type 1 diabetes: a new perspective on who will and who will not progress
WO2006138292A3 (en) Ratiometric test strip and method
CA2574417A1 (en) Timp-2 as target/marker of beta cell failure
Medina-Rosas et al. Proteinuria: assessment and utility in lupus nephritis
WO2008015218A3 (en) Method for diagnosis of a disease involving an anti-at1-receptor antibody
Chen et al. Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients
Maciejczyk et al. Salivary biomarkers in kidney diseases
RU2019144031A (en) METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION
Delcroix et al. NGAL usefulness in the intensive care unit three hours after cardiac surgery
Awad et al. Glomerular and tubular dysfunction in children with congenital cyanotic heart disease: effect of palliative surgery
Pouzot-Nevoret et al. Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model
WO2008057966A3 (en) A panel of biomarkers for peripheral arterial disease
WO2008002911A3 (en) Urate metabolites as diagnostic markers for cardiovascular and renal disease
Sise et al. Elevated urine neutrophil gelatinase-associated lipocalin can diagnose acute kidney injury in patients with chronic kidney diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006826191

Country of ref document: EP